Chart shows buying just beginning to accelerate.
Millennium Healthcare (MHCC) reported revenues increased over 400% in 2014 to over $8 million
Total market cap today at $0.01 per share equals less than $2 million.
At only 10X revenues shares should be selling at $.45 today.
Aggressive growth - Recently acquired HealthPath and MedX with more to be announced
Revenues set to explode again in 2015.
New management is very strong, capable and with strong healthcare relationships.
Expect big runway of new FDA approved early detection diagnostics for heart and cancer.
Small investment has potential for very big gains this year.
Keep MHCC in your portfolio and watch closely for frequent news of big changes
MHCC 12 month price target - $1.25
Sentiment: Strong Buy
This kind of days are not good....sends wrong kind of signal and require major catalyst to change trend. what concerns me is late ER...I am on hold on all front except bought little more HALO just now
I'm a macro trader for the most part and avoid day trading and micro cap stocks. Blcm is the smallest company that I own by mkt cap, while most everything else is 5b and higher. Re technicals, i keep it simple by following trends and using oscillators to add to positions at the most opportune times.
sooz; do you use a charting service, and how accurate has it been, you seem right on with your calls. $130.00 God bless!!! I bought a ton of CPRX around .48 cents, and OPK at $8.65. So far; SO GREAT, not to mention INCY!!!
Sentiment: Strong Buy
Love the pipeline and absolutely love the Lancet news just released. Charts look good and I am buying today. Just thought I would share.
Incy had the breakout over $115, retracement back to the breakout and now poised for $125-130. Looking for a good day today and tomorrow to confirm.
p.s. LLY had a solid quarter!
Bonk, sorry to hear about XOMA - yikes. Good luck with the others. Lilly is showing some strong numbers however pipeline needs strength. No pre-M&A activity on our GEM but have to believe there's some "antsy" potential buyers out there! I think it was Sooz who said they'd love to be in the parking lots watching the Town Cars drive up - I'd like to be stationed near the back door - think that's where they're slipping in!!
Maddie; Thanks for doing math....looks like expected numbers to me...I am just sitting quiet doing next 2-3 weeks ..expect no big move near term. I don't see any pre-M&A activity in our GEM...I am spending more time with ACAD,HALO, & SYN....got burn today with XOMA following Baker Bros.steps..
Jakavi - $18 million (NVS just reported), contract revenue $3 million, Jakafi $138 million (10% increase over 1st quarter) = $159 million.... would not be surprised to be in the $160's.....thoughts everyone?
Lilly! @ 224.00. Now if we can only reduce/get rid of long term capital gains!!! Like the governmnet can waste our money better than us?????
Sentiment: Strong Buy
Nailed it. SGEN will be making/releasing some potentially significant updates at that meeting that could push them from %50 to $75 imho. hence why i bought Dec 50 calls last week in addition to owning the common. i might add that i think they are on the buyout menu for large pharm.
I was scanning for upcoming events and found a new biggie. First ASH meeting on hematologic malignancies, Sept 17-19. Mostly a series of "How I Treat..." presentations by big names (MF presentation by Reuben Mesa, who seems to be unique in getting along with everybody). Some room in the program for breaking news. Abstract submitters to be notified by August 1, so titles may be released soon afterward. The example abstract is full-poster-sized (and incidentally a 2010 Ruxo poster), so I doubt that abstracts will be published before the meeting starts. To attract business to this meeting, ASH will allow material presented at it to be the basis of national meeting (Dec) presentations.
Really wild speculation: the Aug CC is a tad late this year. Might they be anxious to mention abstracts accepted for this meeting?
Sure enough--I missed this before (I said in the 68% increase item that I would look at this)--RESPONSE:
Study Start Date: October 2010
Estimated Study Completion Date: December 2018
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Nominal life expectancy after a diagnosis of PV is 20 years, so the full 8-year study is long enough to pick up a survival signal (not to mention progression to MF or AML).
Sure, my constant refrain is that an investment time frame is about 18 months, but this has some interesting features. First: the earliest date when that telomerase inhibitor could hit the market is 2018, and even then they wouldn't be able to claim a survival benefit. Second: there's a [relatively] large and easy market for indolent and mild MF, and a significant decrease in transitions to MF in this group could help in attacking that market.
To complete the reversal...a 68% YoY increase for Jakavi at this stage of its rollout is not a big deal.
However, I'm going to take a look at the trial description of RESPONSE. The ongoing extension could be real interesting if it continues long enough.